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Abstract
Progerin is a truncated form of lamin A. It is identified in patients with Hutchinson-Gilford progeria syndrome
(HGPS), a disease characterized by accelerated aging. The contribution of progerin toward aging has been shown
to be related to increased DNA damages. Since aging is one major risk factor for carcinogenesis, and genomic
instability is a hallmark of malignant cancers, we investigated the expression of progerin in human cancer cells,
and whether its expression contributes to carcinogenesis. Using RT-PCR and Western blotting, we detected the
expression of progerin in prostate PC-3, DU145 and LNCaP cells at mRNA and protein levels. Ectopic progerin
expression did not cause cellular senescence in PC-3 or MCF7 cells. PC-3 cells progerin transfectants were sensi-
tized to DNA damage agent camptothecin (CPT); and persistent DNA damage responses were observed, which
might be caused by progerin induced defective DNA damage repair. In addition, progerin transfectants were more
tumorigenic in vivo than vector control cells. Our study for the first time describes the expression of progerin in a
number of human cancer cell lines and its contributory role in tumorigenesis.
Introduction
Progerin is a truncated form of lamin A, a major consti-
tuent of nuclear lamina, in which 50 amino acid resi-
dues are deleted near the C-terminus as a result of a
point mutation (1824C > T) in the LMNA gene [1].
This mutation was identified in the majority (80%) of
patients with Hutchinson-Gilford progeria syndrome
(HGPS) [2], a disease characterized by an accelerated
aging process [3]. The nucleotide substitution at posi-
tion 1824 (C to T) in exon 11 of the coding sequence
does not result in an amino acid change (G608G) but
donates a cryptic splice site that leads to a 150 bp
n u c l e o t i d e sd e l e t i o ni ne x o n1 1o fp r e l a m i nAm R N A
[1]. The truncated prelamin A mRNA is translated into
a mutant protein named progerin/LAΔ50 with an inter-
nal 50 amino acid deletion. The loss of 50 amino acids
at the carboxyl terminus of prelamin A compromises its
posttranslational maturation by removing the proteolytic
cleavage site, which is required by an integral membrane
metalloproteinase ZMPSTE24 (FACE-1) mediated dele-
tion of 15 C-terminal amino acids, thus generating a
permanently farnesylated progerin/LAΔ50. Zmpste24-
deficient mouse embryonic fibroblasts (MEFs), with rela-
tively high level of prelamin A expression, share pheno-
typic similarities as HGPS fibroblasts [4].
T h ea c c u m u l a t i o no fp r o g e r i nw i t h i nH G P Sp a t i e n t
fibroblasts or prelamin A in Zmpste24-deficient MEFs
acts in a dominant negative manner, causing DNA
damages and corresponding DNA damage responses
such as constant activation of ATM and ATR, phosphor-
ylation of Chk1, Chk2 and p53 [5,6]. Moreover, HGPS
patient fibroblasts and Zmpste24-deficient MEFs are
more sensitive to DNA-damaging agents and are retarded
in the recruitment of DNA damage response proteins like
p53 binding protein 1 (53BP1), indicating the existence of
defective DNA repair machinery, such as homologous
recombination DNA repair, within these cells [7]. Of
note, the inability to carry out functional DNA damage
repair, especially for double stranded break repair
(DSBR), leads to hypersensitivity to DNA-damaging
agents and pronounced genomic instability.
G e n e t i ci n s t a b i l i t yi sak e yf e a t u r eo ft h em u l t i - s t e p
tumorigenesis. Loss of genomic stability provides muta-
tions in tumor suppressor genes or oncogenes [8,9]. The
present study is undertaken to test the hypothesis that
progerin is expressed in cancer cells and that the protein
may promote tumorigeneis by increasing genomic
instability in cancer cells. We investigated the expression
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eral cancer cells lines. Overexpression of progerin failed
to induce cellular senescence in PC-3 and MCF7 cancer
cells but sensitized PC-3 cells toward DNA damage. The
tumors derived from PC-3 cells with ectopic progerin
expression showed enhanced growth in vivo. Our study is
the first to demonstrate the existence of progerin within
cancer cells and its possible role in tumorigenesis.
Materials and methods
Materials
Human prostate cancer cell lines PC-3, DU145 and
LNCap, breast cancer cell lines MCF7 and MDA-MB-231,
colon carcinoma cell lines SW480, SW620 and HCT116,
and mouse embryonic fibroblast cell line NIH-3T3 were
purchased from American Type Culture Collection.
MCF10A cells (human mammary epithelial cell-line) were
kindly gifted by Randolph C. Elble, Ph.D., the Department
of Pharmacology at Southern Illinois University School of
Medicine. Fetal bovine serum (FBS) and bovine serum
(BS) were purchased from Invitrogen. GFP antibody was
purchased from Clontech; Lamin A/C (sc-20681) and
emerin antibodies were purchased from Santa Cruz bio-
technology; anti-phosphorylated histone-H2AX polyclonal
antibody was from Trevigen. Phospho-Chk2 (Thr68) was
purchased from Cell Signaling Technology, Inc. Two nor-
mal tissues (Normal breast (A804144): 41 y; and Normal
colon (A605057): 21 y and two tumor tissues (Breast
tumor (A810179): 50 y and Colon tumor (A805131): 51 y)
total RNA were purchased from BioChain Institute, Inc.
GenePORTER® liposome was from Genlantis. The senes-
cent cell staining kit was from Sigma-Aldrich. CometAssay
Kit was from Trevigen. pEGFP-lamin A (denoted as
LA-pEGFP), Δ50 pEGFP-lamin A (denoted as progerin-
pEGFP) or a control empty vector were kindly given by
Dr. Tom Misteli, NIH.
Cell culture and plasmids transfection
PC-3, DU145, LNCaP, MDA-MB-231, SW480, SW620
and HCT116 cells were grown in a RPMI 1640 medium
supplemented with 10% FBS and antibiotics-antimyco-
tics (100 units/ml penicillin, 100 μg/ml streptomycin
and 250 μg/ml amphotericin B) in a humidified incuba-
tor under an atmosphere containing 5% CO2 at 37°C.
MCF7 and A431 cells were cultured in a Dulbecco’s
Modified Eagle’sM e d i u m( D M E M )w i t h1 0 %F B Sa n d
antibiotics-antimycotics. NIH-3T3 cells were grown in a
DMEM with 10% BS and antibiotics-antimycotics.
MCF10A cells were cultured in DMEM/F12 medium,
supplemented with Horse Serum, EGF, Hydrocortizone,
CholeraToxin, Insulin, and Pen/Strep. PC-3, MCF7 or
NIH 3T3 growth to 70%-80% confluence were trans-
fected with expressing plasmids using GenePORTER®
liposome transfection reagent following manufacturer’s
instructions. Stable clones were obtained after fluores-
cence activated cell sorting (FACS) and G418 (0.4-0.8
mg/ml) selection.
RT-PCR and real-time PCR
The expression of progerin in established human cancer
cell lines was evaluated by RT-PCR. Total RNA was
extracted from cell cultures with an RNeasy Mini Kit
(QIAGEN) and treated with RNase-free DNase. 2 ug of
RNA were reverse transcribed using oligo-dT primers by
Superscript TM III First-Strand synthesis system (Invi-
trogen). Primers for simultaneous detection of full length
and truncated LMNA isoforms were located in exon 9
and exon 12 of LMNA (LMNA-RT9F: 5’ GTGGAAGG-
CACAGAACACCT-3’; LMNA-RT12R: 5’-GTGAGGAG-
GACGCAGGAA-3’) as described in [10]. End-point PCR
products were separated in 2% agarose gels and stained
with ethidium bromide. Primers for specific detection of
truncated LMNA (progerin) were located across the aber-
rant splice junction and in exon 12 (LMNA-RTspecM3F:
5’ GCGTCAGGAGCCCTGAGC-3’. Three mismatches
were introduced in the primer to avoid primer dimmers
formation and cross hybridization with the full-length
LMNA mRNA; LMNA-RTspec12R: 5’-GACGCAG-
GAAGCCTCCAC-3’). Primers used to amplify all LMNA
transcripts were located across exon 8-exon 9 splice junc-
tion and in exon 9 (LMNA-RTnorm8F: 5’-GGTGGTG
ACGATCTGGGCT-3’; LMNA-Rtnorm9R: 5’-CCAGTG-
GAGTTGATGAGAGC-3’). Samples were analyzed in
triplicate in three independent experiments. Use of the
cryptic splice site in the different cell lines was calculated
by normalizing Δ150 LMNA (progerin) RNA levels to
the total LMNA RNA levels in each sample. Samples
were analyzed in triplicate in three independent experi-
ments. For the real-time quantitative PCR, the reactions
were performed as described by Chen et al [11].
Western blotting
PC-3 cells with stable progerin-pEGFP, LA-pEGFP or
pEGFP vector expression were subjected to different
treatments. The cell lyses were collected with ice-cold
RIPA buffer (Sigma, R0278) in the presence of a pro-
tease inhibitor cocktail (Sigma, S8830). Fifty micrograms
of protein were fractionated by SDS-PAGE gels in a
Bio-Rad Protean II system. After transferring proteins to
a PVDF membrane, the membrane was blocked with
Odyssey Blocking Buffer from LI-COR Biosciences for
60 min at room temperature and incubated with the pri-
mary antibody at appropriate dilutions in Odyssey
Blocking Buffer at 4°C overnight. After overnight incu-
bation with appropriate primary antibodies, the mem-
brane was washed (3×) with TBS-T for a total of
15 min, probed with fluorescently-labeled secondary
antibody (1:5000) for 50 min at room temperature and
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immunoblots were visualized by an Odyssey Infrared
Imaging System (LI-COR).
Immunocytochemistry and Confocal Microscopy
PC-3 cells with stable progerin-pEGFP, LA-pEGFP or
pEGFP vector expression were seeded at 0.3 × 10
6/well
into 6-well plates with coverglasses to achieve 70% con-
fluence. Twenty four hours later, the cells were fixed
with 3% paraformaldehyde in PBS for 15 min, followed
by permeabilization with 0.1% Triton X-100 for 1 min.
After blocking in 1% BSA/1 × PBS containing 3% horse
serum for 30 min, the slides were incubated with pri-
mary antibody against Lamin A/C (Santa cruz biotech-
nology, inc.) with 50 fold dilution for 1 h, washed three
times with PBS and then incubated with Alexa Fluor®
568 goat anti-mouse IgG (H+L) secondary antibody for
1 h (1: 100 dilution each). The slides were then washed
three times with PBS, counterstained in Prolong® Gold
antifade reagent with DAPI and visualized with a BX41
system microscope (Olympus) or with an Olympus
Fluoview confocal microscope using a 100× oil immer-
sion objective lens (IX70 Olympus, Melville, NY, USA).
Fluorescence was excited by the 488-nm line of an
argon laser and the 568/647-nm line of a Krypton laser.
Images were analyzed using Fluoview software.
Senescence-associated b-galactosidase (SA b-Gal) staining
PC-3 cells with stable progerin-pEGFP, LA-pEGFP or
pEGFP vector expression were seeded in six-well plates.
When reaching 70% confluence, the cells were washed
twice with PBS and fixed in fixation buffer containing
2% formaldehyde/0.2% glutaraldehyde in PBS for 7 min
at room temperature. SA-b-gal staining was performed
in fresh senescence-associated X-Gal staining solution
containing 1 mg/ml of 5-bromo-4-chloro-3-indolyl beta-
D-galactoside (X-Gal), pH 6.0, 5 mM potassium ferro-
cyanide, 5 mM potassium ferricyanide and 2 mM MgCl2
in PBS at 37°C (no CO2). Incubation typically lasted for
1 6h .C e l l sw e r er i n s e di nP B Sa n ds t o r e di nP B Sw i t h
70% glycerol. Cells were then examined under a micro-
scope at Χ200 magnification for a blue-green staining of
the cytoplasm indicative of senescence.
Estimation of DNA damage by comet assay
We performed the comet assay on Comet Slide (Trevi-
gen) following the manufacturer’s instructions. Briefly,
the cells were treated with camptothecin (0.1 μM) for
12 hours and the extent of DNA damage was measured
48 hours later. Dakin-frosted slides were covered with
100 ml of 0.6% normal melting point agarose, and the
agarose was allowed to solidify under a cover slip on
ice. The cover slips were then removed. Subsequently,
aliquots (1 ml) of harvested cells containing 1 × 10
5
cells in culture medium were then centrifuged to pellets.
The pellets were resuspended in 80 μl of 0.6% low melt-
ing point agarose, layered onto the normal melting
point agarose and allowed to solidify under a fresh
cover slip on ice. All the steps described were conducted
under a reduced light level to prevent additional DNA
damage. Slides were then placed immediately in a cold
lysis buffer for 1 hour. After lysis, the slides were
drained and placed in a horizontal gel electrophoresis
t a n k ,s u r r o u n d e db yi c ea n df i l l e dw i t hf r e s hc o l de l e c -
trophoresis buffer to a level of ~0.25 cm above the
slides. Slides were kept in the high pH buffer for 20
min, to allow DNA unwinding. Electrophoresis was then
carried out for 20 min at 25 V and 300 mA. The slides
were stained with SYBR Green and covered with a cover
slip for immediate analysis. The slides were observed
with a BX41 fluorescence microscope (Olympus, Center
Valley, PA) and more than 100 cells were analyzed to
give a representative result for the population of cells.
The parameters of comet images such as the length of
the tail moments were calculated using Comet Assay IV
software (Perceptive Instruments Ltd).
Cell viability measurement
Cell viability was measured with Vi-CELL™ Series Cell Via-
bility Analyzers (Beckman Coulter, Inc.), which is based on
traditional cell viability method of trypan blue exclusion.
Animal model and histology
PC-3 (4 × 10
6) cells with stable progerin-pEGFP, LA-
pEGFP or pEGFP vector expression were injected sub-
cutaneously into nude mice. Five groups of nude mice
were utilized. Tumor development was monitored 1
week after implantation. About 38 days after implanta-
tion, the experiment was terminated and the animals
were sacrificed. Primary tumors were removed and fixed
for hematoxylin & eosin staining and immunohisto-
chemical analysis. Mitotic and apoptotic figures in
tumor sections stained with H&E were counted through
the microscope by trained technicians with a mechanical
tabulator, in a double blind approach. Total background
cells in each field were also counted and the percentage
of positive cells [(X positive/Y total count) × 100] was
calculated for each tumor.
Statistical analysis
The probability of statistically significant differences
between two experimental groups was determined by
Student’s t-test. P < 0.05 was considered statistically sig-
nificant in all calculations.
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Abnormal nuclear envelope proteins distribution in
human cancer cell lines
Nuclear envelope (NE) abnormality is an important diag-
nostic marker in a plethora of human cancers [12,13]. In
sharp contrast to the nearly spherical shape of the NE in
most normal cells, the NE of cancer cells predominantly
displays irregularities characterized as passive distortion,
increased chromatin aggregation, and deep infoldings. As
shown in Figure 1a, immunocytostaining of lamin A
revealed substantial nuclear lamina invaginations and bleb-
bings in A431, MDA-MB-231, MCF7 and PC-3 cells, simi-
lar to those described in HGPS cells. In addition, emerin,
which is an integral membrane protein and directly inter-
acts with nuclear lamins, also displayed pronounced invagi-
nations and blebbings distribution (Figure 1b).
Existence of progerin in human cancer cell lines
Most HGPS cases are caused by a nucleotide substitu-
tion at position 1824 (C to T) related 150 nucleotides
deletion within LMNA mRNA [1]. We determined
whether cancer cells also harbor mutant lamin A (pro-
gerin) using RT-PCR with primers that can simulta-
neously detect both the full-length (F) LMNA mRNA
(510 bp) and the truncated (T) LMNA isoform/progerin
(360 bp) (Figure 2a). The 510 and 360 bp fragments of
the PCR products amplified from PC-3, DU145 and
LNCaP cells were detected (Figure 2b).
Quantitative RT-PCR analysis using the splice junction
primers demonstrated that use of the cryptic splice site
(progerin) was about 38-fold higher in a number of cancer
cell lines than in a normal human mammary epithelial
cell-line (MCF10A) (Figure 2Ci). Use of the cryptic splice
site is not because of cell-culture artifact, because Δ150
LMNA (progerin) mRNA is also detectable in human tis-
sues (Figure 2Cii). Similar to cultured cells, we observed a
20-fold higher progerin mRNA level in human tumor tis-
sues than it from normal human tissues (Figure 2Cii). In
our study, the detection of progerin mRNA from human
normal tissues, albeit at very low level compared with that
from tumor tissue, is in agreement with a previous report
that Δ50 lamin A (progerin) is present in cells from
healthy individuals [10]. Sequence data confirmed the pre-
sence of expected lamin transcript fragments and muta-
tion-related specific nucleotide fragments (Figure 2D).
Further, western blotting was performed with primary
antibody which simultaneously detects lamin A/C and
progerin. An additional band is present between the lamin
A and lamin C bands in all cell lines examined. The band
is 3.8 kD lower than lamin A and is in consistent with the
expected molecular weight of progerin (Figure 2E). Taken
together, we conclude that progerin is expressed in a num-
ber of human cancer cell lines.
Ectopic progerin expression in cancer cells
To study the effects of progerin expression on cancer
cells, PC-3 or MCF7 cells were transfected with wild type
pEGFP-lamin A (LA-pEGFP), Δ50 pEGFP-lamin A (pro-
gerin-pEGFP) or a backbone vector. NIH-3T3 cells were
also transformed. The expression of GPF fused progerin
or wild type lamin A was confirmed with western blot-
ting and immunocytostaining (Figure 3a, c and 3e). Ecto-
pic progerin expression in NIH-3T3 cells resulted in
blebbings, invaginations and cytoplasmic aggregates on
the nuclear membrane, similar to those observed in
HGPS fibroblasts (Figure 3b) [14,15]. In contrast, homo-
geneous and smooth distribution of LA-pEGFP was
observed in cells transfected with the LA-pEGFP expres-
sion construct (Figure 3b). The results confirmed the det-
rimental effects of progerin on nuclear lamina
distribution. Similarly, ectopic progerin expression in PC-
3 or MCF7 cells was associated with prominently exacer-
bated intra-nuclear structures including nuclear invagina-
tions and blebbings (Figure 3d and 3e). However, as
different from the homogenous LA-pEGFP distribution in
NIH-3T3 cells, LA-pEGFP displayed aberrant distribution
in PC-3 and MCF7 cells (Figure 3d and 3e).
Ectopically expressed progerin failed to induce cellular
senescence in the cancer cells
Primary cultured cells can undergo cellular senescence in
vitro, withdrawing from cell cycle progression. In con-
trast, malignant tumor cells can proliferate endlessly and
rarely undergo cellular senescence in vitro [16]. A hall-
mark of HGPS fibroblasts and skin fibroblasts from a
Figure 1 Abnormal distribution of nuclear envelope proteins in
human cancer cell lines. Immunocytostaining of PC-3, MDA-MB-
231, MCF7 and A431 with antibody against Lamin A (A) or emerin
(B). Representative images of cells were taken with a fluorescence
microscope at 400 × magnification (A) or 600 × magnification (B).
Note the invaginations and blebbings pattern of Lamin A and
emerin distribution. (C) Immunocytostaining of Lamin A in
immortalized and non-malignant NIH 3T3 cells (Mouse embryonic
fibroblast cell line) and MCF10A cells (human mammary epithelial
cell-line). Representative images of cells were taken with a
fluorescence microscope at 600 × magnification.
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to cellular senescence [14]. In this study, PC-3 cells trans-
fected with either LA-pEGFP or progerin-pEGFP did not
show marketed difference in proliferation (Figure 4a).
Additionally, no noticeable difference regarding the cellu-
lar senescence, reflected by b-gal positively staining, was
observed in PC-3 or MCF7 cells with ectopic progerin
expression (Figure 4b). This finding indicates that the
ectopic progerin expression failed to induce cellular
senescence in PC-3 or MCF7 cells.
Impaired DNA repair mechanisms in PC-3 cells with
ectopic progerin expression
Progerin acts in a dominant negative manner to perturb
DNA damage response and repair. The accumulation of
progerin promote the cells’ sensitivity to DNA-damaging
agents, including ultraviolet irradiation and chemicals
causing double-strand breaks (DSBs), which contributes
to genomic instability in HGPS fibroblasts [7]. To deter-
mine whether progerin expression would perturb DNA
repairs, we treated the cells with camptothecin, which
generates double stranded DNA breaks (DSBs) by inhi-
biting eukaryotic DNA topoisomerase I [17]. Particu-
larly, we focused on H2AX, which is phosphorylated (g-
H 2 A X )a tt h es i t e so fd o u b l e - s t r a n d e dD N Ab r e a k st o
initiate DNA damage checkpoint responses, thereby act-
ing as the direct marker of DNA damage; and Chk2,
which is an important component of the DNA damage
checkpoint response [18]. Using immunofluorescence
staining, we observed more g-H2AX and Chk2 foci in
Figure 2 Existence of progerin in human cancer cell lines. (A) The 12-exon of Lamin A transcript is presented. The cryptic splice site (red
box) and the position of the primer set used for RT-PCR is indicated. (B) RT-PCR analyses of progerin transcription in different cancer cells using
primers detecting both the full-length (F) and the truncated (T) LMNA isoforms. All PCR products were confirmed by DNA sequencing. (C)
Quantitative real time PCR analysis progerin or LMNA from a number of cancer cells (i), a human mammary epithelial cell-line (i), normal and
tumor human tissues (ii). Δ150 LMNA RNA was detected by using Dex11-ex12 primers relative to total LMNA RNA detected by using ex8-ex9
primers is shown. (D) Sequencing of progerin and wildtype LMNA RT-PCR product from PC-3 cells. Progerin specific mRNA sequence
(GGAGCCCAGAGCCCCCAGA) was compared with the normal LMNA sequence (GGAGCCCAGGTGGGCGGAC). (E) Western blotting of total cell
lyses from PC-3, DU145, LNCAP, and MDAMB231 with Lamin A antibody, which detects lamin A/C and progerin simultaneously.
Tang et al. Cancer Cell International 2010, 10:47
http://www.cancerci.com/content/10/1/47
Page 5 of 10PC-3 cells with ectopic progerin expression, indicating
higher DNA damage in these cells (Figure 5a and 5b).
Increased DNA damage was further confirmed by wes-
tern blotting, which showed elevated phosphorylation
of g-H2AX and Chk2 at Thr68 (Figure 5c). Thus, PC-3
cells with progerin expression showed elevated sensi-
tivities to the DNA-damaging agent, while the presence
of phosphorylated g-H2AX and Chk2 indicates com-
promised DNA damage repair mechanisms in those
cells.
Figure 3 Ectopic progerin expression in cancer cells. NIH-3T3 cells were transfected with different lamin A expression constructs or the
vector control. (A) Total cell lysates were probed with GFP antibody for Western blotting. (B) Representative images of cells were taken with a
fluorescence microscope at 600 × magnification. Note that, ectopic expression of progerin exacerbated nuclear lamina distribution by inducing
nuclear blebbings and invaginations (low panel), indicated by arrows. (C) PC-3 and MCF7 cells were transfected with lamin A expression
constructs or vector control. Total cell lysates of PC-3 cells were probed with GFP antibody (i) or GFP and Lamin A/C antibody (ii) for Western
blotting. (D) Representative images of cells were taken with a fluorescence microscope at 400 × magnification. (E) The PC-3, MCF7 and NIH-3T3
cells were transfected with Lamin A or progerin expression constructs. The cells were stained with Lamin A antibody. Representative images
were obtained with an Olympus Fluoview confocal microscope using a 100× oil immersion objective lens.
Figure 4 Ectopically expressed progerin failed to induce cellular senescence in the cancer cells.( A )T h eg r o w t hc u r v eo fP C - 3c e l l s
transfected with lamin A expression constructs or vector control was performed with a MTS assay. The bars represent the mean ± SE (n = 4). (B)
SA-beta-Gal staining of PC-3 cells transfected with different lamin A expression constructs or vector control. Photomicrographs were taken at 200
× magnification. Percentages of SA-beta-Gal positive staining were presented below. *P < 0.01, compared with pEGFP vector transfected group.
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responses result from defective DNA repair, we applied
alkaline comet assay to determine the DNA strand breaks
[19]. The CPT treatment led to significant increase in the
DNA damage in PC-3 cells with ectopic progerin expres-
sion as evidenced by elongated comet tail length and
higher tail movement compared with those cells trans-
fected with wild type lamin A (Figure 5d). The results
indicate that the ectopic progerin expression compro-
mises DNA repair in PC-3 cells. The delayed DNA
damages repair response and the accumulation of
impaired DNA in PC-3 cells with progerin expression
potentiated the sensitivity of the cells toward CPT
induced cell death (Figure 5e).
Elevated tumorigeneis of PC-3 cells with ectopic progerin
expression
Genomic instability is a step in multi-step tumorigenesis
[8,9,20]. Genomic instability provides increased chances
for the occurrence of DNA mutation related tumor sup-
pressor genes malfunction or oncogenes hyperactivation,
both of which are critical for tumor progression and
growth [8,9,20]. To investigate whether a compromised
DNA repair caused by ectopic progerin expression facili-
tates tumorigenesis of cancer cells in vivo, we injected
PC-3 cells with the expression of LA-pEGFP, progerin-
pEGFP or an empty plasmid pEGFP vector into nude
mice, respectively. As shown in Figure 6a, tumors derived
from PC-3 cells with progerin-pEGFP expression grew
Figure 5 Impaired DNA repairs in PC-3 cells with ectopic progerin expression. PC-3 cells were transfected with different lamin A expression
constructs or vector control. The cells were treated with CPT (0.1 μM) for 12 hours and 48 hours later, the cells were stained with either g-H2AX
(A) or Phospho-Chk2 (Thr68) (B) antibody. Representative images of cells were taken with a fluorescence microscope at 400 × magnification. (C)
PC-3 cells were transfected with different either progerin-pEGFP or LA-pEGFP as control. The transfected cells were treated with CPT (0.1 μM)
with the indicated times. The total cell lysates were probed with either g-H2AX or Phospho-Chk2 (Thr68) antibody. (D) Representative
photomicrographs of the comet assay showing the DNA migration pattern. Representative images of cells were taken with a fluorescence
microscope at 600 × magnification. Relative lengths of the DNA tail and Tail moments are presented as below. The bars represent the mean ±
SE (n = 20). *P < 0.01; ** P < 0.001, compared with PBS control at the corresponding time. (E) The cells were treated with CPT (0.5 μM) for 12
hours and 48 hours, the cell viability was measured by trypan blue exclusion based cell staining.
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trols. Histological evaluation revealed an increase in mito-
tic index in tumors with progerin expression (Figure 6b).
No statistically significant differences regarding the apop-
totic index were found in tumors derived from progerin-
transfected cells when compared to that of control
tumors (Figure 6c). Taken together, the data suggest that
progerin promotes the tumorigenic potential of PC-3
cells.
Discussion
In the present study, the expression of progerin, a trun-
cated form of lamin A protein, was detected in several
human cancer cell lines. Ectopic expression of progerin
in PC-3 and MCF7 cells compromised the DNA damage
responses and repair, but did not induce cellular senes-
cence. Importantly, an enhanced progerin expression
conferred PC-3 cells with stronger tumorigenic potential
in vivo. Together, these data showed that progerin, the
origin of progeria disease (HGPS), may promote tumor
genomic instability and contribute to tumorigenesis.
Progerin compromises the DNA damage repairs in
HGPS fibroblasts. The defective response to DNA
damages causes persistent activation of DNA damage
responses proteins, such as g-H2AX and p53-BP [4-7]. To
clarify the effects of progerin expression in cancer cells, we
introduced progerin and wildtype lamin A into prostate
cancer PC-3, breast cancer MCF7 cells and mouse fibro-
blast NIH-3T3 cells. The nuclear envelope of NIH-3T3
progerin transfectants displayed blebbings, invaginations
and cytoplasmic aggregates, similar to those in HGPS
fibroblasts (Figure 3b), consistent with the dominant nega-
tive effects of progerin on nuclear lamina. When PC-3 or
MCF7 cells were transfected with progerin, noticeable
nuclear membrane invaginations were observed. Interest-
ingly, the introduced wildtype lamin A existed at an inva-
ginated pattern as well (Figure 3d and 3e). Divergent
patterns of LA-pEGFP distribution in NIH-3T3 and
cancer cell lines are probably due to the existence of endo-
genous progerin in cancer cells. Progerin only has a
50 C-terminal amino acid deletion from lamin A while
retaining the central coiled-coil domain [21]. This indi-
cates that exogenous LA-pEGFP may associate with endo-
genous progerin to form heterodimers through the coiled
coil domains of the central rod region, thus reflecting the
endogenous progerin distribution within the nuclear
Figure 6 Elevated tumorigeneis of PC-3 cells with ectopic progerin expression. (A) Five-week growth kinetics of the tumors derived from
PC-3 with stable Lamin A, progerin or vector expression. Data point, mean volume of 5 tumors for each group; Data point, mean volume of five
tumors; bars, STD. (B) Mitotic index. Mitotic figures were counted in 400× fields and expressed as the percentage of the total cells. Columns,
mean mitotic index in tumors; bars, STD. Note the significant increase in mitotic figures in tumors derived from progerin transfectants (n = 5) as
compared to those of LA-pEGFP transfectants (n = 5) (p < 0.001 by Student’s t test). (C) Apoptotic index. Apoptotic figures were counted in
400× fields and the index expressed as the percentage of the total cells in the same field. Columns, mean apoptotic index in tumors; bars, STD.
(p < 0.01 by Student’s t test).
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Page 8 of 10envelope. On the other hand, our results are in agreement
with the observation that introduction of wildtype lamin A
protein does not rescue the cellular symptoms within
fibroblast from HGPS patients [15].
A hallmark of HGPS fibroblasts and skin fibroblasts
from a mouse model of progeria is their premature cellu-
lar senescence [14]. The cellular senescence may be due
to the increased DNA damages and corresponding cellu-
lar DNA damage responses [5-7]. In our study, we did
not observe a significant difference regarding the prolif-
eration rate of PC-3 cells expressing either progerin or
vector control in vitro (Figure 4a). Introduced progerin
failed to induce cellular senescence within PC-3 and
MCF7 cells (Figure 4b). However, we observed increased
DNA damages and persistent activation of DNA damage
repair proteins, such as g-H2AX and Chk2, in PC-3 pro-
gerin transfectants (Figure5 ) ,w h e nt h ec e l l sw e r es u b -
jected to the DNA-damaging agent CTP. The results are
consistent with earlier observations that progerin acts in
a dominant fashion to trigger DNA repair defects
[7,14,15]. A variety of factors involved in detecting and
responding to DNA damage are altered in human
tumors. Genotoxic stresses and genomic stabilities
caused by defective DNA damage repair contribute to
tumorigenesis [8,9,20]. In our study, tumors derived from
PC-3 progerin transfectants grew much faster than those
derived from control groups (Figure 6a). The increased
growth rate is associated with higher mitotic index, while
the apoptotic index is similar to that of control group
(Figure 6b and 6c). Compared with those cells cultured
in vitro,t h ein vivo transplanted cells are encountered
with much more adverse environment, such as limitation
of nutrient and oxygen supply primarily due to a poorly
developed and/or malfunctioning vascular network,
which might be associated with hypoxic stress, oxidative
stress, increased DNA damages and genomic instability.
Most of those factors would contribute to the enhanced
tumorigenesis of the cancer cells.
Interestingly, a recent study by Marinõ et al. reported
that an extensive basal activation of autophagy occurs in
Zmpste24-null mice, which show accelerated aging and
is a reliable model of human Hutchinson-Gilford pro-
geria [22]. Autophagy may restrain tumorigenesis by
maintaining genome stability, which is pivotal for coping
with metabolic stress encountered by established aggres-
sive tumors [23]. It is believed that nuclear abnormal-
ities causing premature aging in Zmpste242/2 mice
trigger a metabolic response involving the activation of
autophagy [22]. Nevertheless, the underlying induction
and regulation mechanisms responsible for the elevated
autophagy flux in progeria mouse model await further
investigation. The study might partially explain the pro-
gerin promoted tumorigeneis of PC-3 cells in our study.
To elucidate whether ectopic progerin expression could
render the non-malignant/transformed cells with tumori-
genesis ability, we transfected NIH-3T3 cells with either
LA-pEGFP or progerin-pEGFP and tried to establish NIH-
3T3 sublines that stably express those proteins. However,
the efforts are hampered by the growth disadvantages pre-
sented by the NIH-3T3 cells with ectopic progerin-pEGFP
expression. Meanwhile, we think progerin promoted
tumorigenesis is based on its ability to compromise func-
tional DNA-damage repair, which is important to main-
tain the genomic integrity when the tumors reach the size
limits where suppressed nutrient and oxygen supply con-
tributes to the hypoxic and oxidative stress. In another
word, progerin expression would not promote the tumori-
geneis at its very initial stage of tumor development.
In summary, here we report for the first time that pro-
gerin, a mutated lamin A that occurs in a rare genetic dis-
order characterized by premature senescence, is expressed
in a variety of established human cancer cell lines.
Although PC-3 cells transfected with progerin did not
show any phenotype of cellular senescence, there were
increased DNA damages and persistence of DNA damage
responses in the progerin transfectants after CPT treat-
ment. Progerin transfectants displayed increased tumori-
genesis ability in vivo, probably due to heightened
genomic instabilities. Finally, given the efficiency of farne-
syltransferase (FTase) inhibitors (FTIs) in the nuclear
architecture rescue of human HGPS fibroblasts and a
broad spectrum of human cancer treatments, the targeting
of progerin may open a new avenue for human cancer
therapy [24-27].
Abbreviations used
HGPS: Hutchinson-Gilford progeria syndrome; ATM: ataxia telangiectasia
mutated; ATR: ataxia telangiectasia mutated and rad3-related.
Conflict of interests
The authors declare that they have no competing interests.
Acknowledgements
The authors would like to thank Dr. Tom Misteli, National Institute of Health
(Bethesda, MD, USA) for providing the progerin expression constructs. We
also would like to thank Gregory T. Robbins for his critical proofreading.
Authors’ contributions
YT and DN conceived the project and designed the experiments. YT, YC and
HJi performed the studies. YT prepared and DN edited the manuscript. DN
gave approval for the final version to be submitted.
Received: 11 May 2010 Accepted: 24 November 2010
Published: 24 November 2010
References
1. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I,
Lyonnet S, Stewart CL, Munnich A, Le Merrer M, et al: Lamin a truncation
in Hutchinson-Gilford progeria. Science 2003, 300(5628):2055.
2. H G: Progeria: a form of senilism. Practitioner 1904, 73:188-217.
3. Hennekam RC: Hutchinson-Gilford progeria syndrome: review of the
phenotype. Am J Med Genet A 2006, 140(23):2603-2624.
Tang et al. Cancer Cell International 2010, 10:47
http://www.cancerci.com/content/10/1/47
Page 9 of 104. Pendas AM, Zhou Z, Cadinanos J, Freije JM, Wang J, Hultenby K, Astudillo A,
Wernerson A, Rodriguez F, Tryggvason K, et al: Defective prelamin A
processing and muscular and adipocyte alterations in Zmpste24
metalloproteinase-deficient mice. Nat Genet 2002, 31(1):94-99.
5. Liu Y, Rusinol A, Sinensky M, Wang Y, Zou Y: DNA damage responses in
progeroid syndromes arise from defective maturation of prelamin A. J
Cell Sci 2006, 119(Pt 22):4644-4649.
6. Varela I, Cadinanos J, Pendas AM, Gutierrez-Fernandez A, Folgueras AR,
Sanchez LM, Zhou Z, Rodriguez FJ, Stewart CL, Vega JA, et al: Accelerated
ageing in mice deficient in Zmpste24 protease is linked to p53
signalling activation. Nature 2005, 437(7058):564-568.
7. Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, Huang JD, Li KM,
Chau PY, Chen DJ, et al: Genomic instability in laminopathy-based
premature aging. Nat Med 2005, 11(7):780-785.
8. Fishel R: Genomic instability, mutators, and the development of cancer:
is there a role for p53? J Natl Cancer Inst 1996, 88(22):1608-1609.
9. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human
cancers. Nature 1998, 396(6712):643-649.
10. Scaffidi P, Misteli T: Lamin A-dependent nuclear defects in human aging.
Science 2006, 312(5776):1059-1063.
11. Chen Y, Tang Y, Wang MT, Zeng S, Nie D: Human pregnane X receptor
and resistance to chemotherapy in prostate cancer. Cancer Res 2007,
67(21):10361-10367.
12. Fischer AH, Taysavang P, Jhiang SM: Nuclear envelope irregularity is
induced by RET/PTC during interphase. Am J Pathol 2003,
163(3):1091-1100.
13. Fischer AH, Taysavang P, Weber CJ, Wilson KL: Nuclear envelope
organization in papillary thyroid carcinoma. Histol Histopathol 2001,
16(1):1-14.
14. Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB,
Gruenbaum Y, Khuon S, Mendez M, Varga R, et al: Accumulation of mutant
lamin A causes progressive changes in nuclear architecture in
Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2004,
101(24):8963-8968.
15. Scaffidi P, Misteli T: Reversal of the cellular phenotype in the premature
aging disease Hutchinson-Gilford progeria syndrome. Nat Med 2005,
11(4):440-445.
16. Campisi J: Cancer, aging and cellular senescence. In Vivo 2000,
14(1):183-188.
17. Wang Y, Perrault AR, Iliakis G: Down-regulation of DNA replication in
extracts of camptothecin-treated cells: activation of an S-phase
checkpoint? Cancer Res 1997, 57(9):1654-1659.
18. Kastan MB, Lim DS: The many substrates and functions of ATM. Nat Rev
Mol Cell Biol 2000, 1(3):179-186.
19. Moneef MA, Sherwood BT, Bowman KJ, Kockelbergh RC, Symonds RP,
Steward WP, Mellon JK, Jones GD: Measurements using the alkaline
comet assay predict bladder cancer cell radiosensitivity. Br J Cancer 2003,
89(12):2271-2276.
20. Loeb LA: Mutator phenotype may be required for multistage
carcinogenesis. Cancer Res 1991, 51(12):3075-3079.
21. Aebi U, Cohn J, Buhle L, Gerace L: The nuclear lamina is a meshwork of
intermediate-type filaments. nature 1986, 323:560-564.
22. Marino G, Ugalde AP, Salvador-Montoliu N, Varela I, Quiros PM, Cadinanos J,
van der Pluijm I, Freije JM, Lopez-Otin C: Premature aging in mice
activates a systemic metabolic response involving autophagy induction.
Hum Mol Genet 2008, 17(14):2196-2211.
23. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, Chen G,
Jin S, White E: Autophagy suppresses tumor progression by limiting
chromosomal instability. Genes Dev 2007, 21(11):1367-1381.
24. Young SG, Fong LG, Michaelis S: Prelamin A, Zmpste24, misshapen cell
nuclei, and progeria–new evidence suggesting that protein farnesylation
could be important for disease pathogenesis. J Lipid Res 2005,
46(12):2531-2558.
25. Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN,
Gordon LB, Der CJ, Cox AD, Collins FS: Inhibiting farnesylation of progerin
prevents the characteristic nuclear blebbing of Hutchinson-Gilford
progeria syndrome. Proc Natl Acad Sci USA 2005, 102(36):12879-12884.
26. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M,
Sanz G, Poignet H, Skrzat S, et al: Characterization of the antitumor effects
of the selective farnesyl protein transferase inhibitor R115777 in vivo
and in vitro. Cancer Res 2001, 61(1):131-137.
27. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N: A
peptidomimetic inhibitor of farnesyl:protein transferase blocks the
anchorage-dependent and -independent growth of human tumor cell
lines. Cancer Res 1995, 55(22):5302-5309.
doi:10.1186/1475-2867-10-47
Cite this article as: Tang et al.: Promotion of tumor development in
prostate cancer by progerin. Cancer Cell International 2010 10:47.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tang et al. Cancer Cell International 2010, 10:47
http://www.cancerci.com/content/10/1/47
Page 10 of 10